12 completed, 2 unknown. 8 Phase 1, 6 Phase 2, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 8 |
| Phase 2 | 6 | Completed 4, Unknown 2 |
| Phase 3 | 4 | Completed 2, Unknown 2 |
Follow ravidasvir: new trials by email Literature Review of ravidasvir trials Research Report on ravidasvir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 8- Versus 12-week of Sofosbuvir-ravidasvir Treatment of Chronic Hepatitis C Sofosbuvir 400 MG, Ravidasvir 200mg - Hepatitis C | Phase 2 / Phase 3 | Completed | Muhammad Radzi Abu Hassan | 322 | 2021-03-23 | 2025-03-13 |
| A Study of the Relative Bioavailability of ASC18 Tablets vs Reference Tablets in Healthy Volunteers ASC18, ravidasvir and sofosbuvir - Healthy | Phase 1 | Completed | Ascletis Pharmaceuticals Co., Ltd. | 50 | 2020-03-20 | 2021-01-11 |
| A Study to Evaluate the Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in China Ravidasvir 50mg, Ravidasvir 200mg - Chronic Hepatitis c | Phase 1 | Completed | Ascletis Pharmaceuticals Co., Ltd. | 12 | 2018-01-15 | 2018-06-29 |
| Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in China Danoprevir, Ritonavir, Ravidasvir - HCV | Phase 1 | Completed | Ascletis Pharmaceuticals Co., Ltd. | 18 | 2017-08-08 | 2018-01-17 |
| Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, Chronic Hepatitis C Virus Genotype1 Infected Subjects. Ravidasvir, Danoprevir, Ritonavir - HCV | Phase 2 / Phase 3 | Completed | Ascletis Pharmaceuticals Co., Ltd. | 425 | 2017-07-01 | 2020-07-28 |
| Strategic Transformation of the Market of HCV Treatments sofosbuvir + ravidasvir - Hepatitis C | Phase 2 / Phase 3 | Unknown | Drugs for Neglected Diseases | 603 | 2016-09-01 | 2021-01-20 |
| Pharmacokinetics and Safety of Ravidasvir and Danoprevir/r in Healthy Volunteers China Ravidasvir, Danoprevir, Ritonavir - Healthy | Phase 1 | Completed | Ascletis Pharmaceuticals Co., Ltd. | 18 | 2016-07-15 | 2018-06-29 |
| Efficacy and Safety of Ravidasvir + Danoprevir/r 12-week Oral Therapy in Treatment-Naive Non Cirrhotic G1 CHC Taiwan Ravidasvir, Danoprevir, Ritonavir - Chronic Hepatitis C | Phase 2 | Completed | Ascletis Pharmaceuticals Co., Ltd. | 38 | 2015-08-01 | 2020-10-22 |
| A Study of the Efficacy and Safety of PPI-668 (NS5A Inhibitor) Plus Sofosbuvir, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype-4 ravidasvir hydrochloride, sofosbuvir, ribavirin - Chronic Hepatitis C | Phase 2 / Phase 3 | Unknown | Pharco Pharmaceuticals | 300 | 2015-01-01 | 2016-04-07 |
| Phase 1 Study of Relative Bioavailability of PPI-668 New Tablet Versus Capsule Formulations PPI-668 tablet, PPI-668 capsule - Pharmacokinetic Assessments in Healthy Volunteers | Phase 1 | Completed | Presidio Pharmaceuticals, Inc. | 12 | 2014-10-01 | 2015-01-22 |
| Phase 1 Study of Relative Bioavailability of PPI-668 Tablet and Capsule Formulations PPI-668 capsule, PPI-668 tablet - Pharmacokinetic Assessments in Healthy Volunteers | Phase 1 | Completed | Presidio Pharmaceuticals, Inc. | 24 | 2013-10-01 | 2014-01-09 |
| Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis C PPI-668, BI 207127 Dose 1, BI 207127 Dose 2 - Chronic Hepatitis C | Phase 2 | Completed | Presidio Pharmaceuticals, Inc. | 38 | 2013-05-01 | 2015-11-25 |
| A Drug Interaction Study of the Effects of PPI-668 on the Pharmacokinetics of Midazolam and Omeprazole PPI-668, Midazolam, Omeprazole - Pharmacokinetic Assessments in Healthy Volunteers | Phase 1 | Completed | Presidio Pharmaceuticals, Inc. | 24 | 2013-02-01 | 2013-03-26 |
| A Phase 1 Study of PPI-668 in Healthy Volunteers and Patients With Hepatitis C Virus (HCV) Genotype 1 PPI-668, Placebo - Hepatitis C, Chronic | Phase 1 | Completed | Presidio Pharmaceuticals, Inc. | 82 | 2011-10-01 | 2012-11-16 |
Hepatitis C, Chronic (5) · Hepatitis C (3) · Liver Diseases (1) · Virus Diseases (1)
Ascletis Pharmaceuticals Co., Ltd. (6) · Presidio Pharmaceuticals, Inc. (5) · Drugs for Neglected Diseases (1) · Muhammad Radzi Abu Hassan (1) · Pharco Pharmaceuticals (1)
United States (5) · China (4) · Malaysia (2) · Australia (1) · Egypt (1) · New Zealand (1) · Thailand (1)
Nathaniel Brown, MD (3) · Huoling Tang, PhD (2) · Yahong Chen, Master (2) · Gamal Esmat, M.D. (1) · Isabelle Andrieux-Meyer, MD (1) · Muhammad Radzi Abu Hassan, FRCP (1) · Nathaniel Brown, M.D. (1) · Paul Rice, MD (1) · Satawat Thongsawat, MD (1) · Soek-Siam Tan, MD (1) · Yahong Chen, MD (1)
PMID 34252301, PMID 28935432, PMID 33865507, PMID 42140479, PMID 42277657